High resolution structures visible with the 25 nm zone plate objective. by Kamal L. Nahas (13014698)

“…(<b>G</b>) Bulging of the nuclear envelope is observed (arrows). We initially observed these in HSV-1 infection and thought it may represent a virus-directed decrease in the integrity of the nuclear envelope, but we found multiple examples in uninfected cells suggesting that they are a characteristic of U2OS cells. …”

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)

<i>ING3</i> knockout decreases pan-H4Ac and BRD4 levels and stimulates HIV-1 transcriptional initiation and elongation upon addition of AZD5582. by Emily Hsieh (377992)

“…As quality control, we determined the signal levels of RNA-Pol2-S5p from the CUT&Tag data and confirmed the replicates of the antibody was most highly correlated amongst the RNA-Pol2-S5p replicates (<b><a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1011101#ppat.1011101.s011" target="_blank">S3B Fig</a></b>). …”

BH3 Peptides induces a decrease in mitochondrial membrane potential but does not engage the Permeability Transition Pore. by Emelyn H. Shroff (163459)

Rac and PKB activities are required for a late phase of cerebellar LTP. by Claire Jackson (362873)

“…<p><b>A</b>) Addition of the Rac inhibitor EHT1864 (50 µM; n = 7) to pipette solution decreases LTP duration. …”

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Subjects:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects: